Combined administration of meningococcal serogroup B outer membrane vesicle vaccine and conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic

Clinical and Diagnostic Laboratory Immunology

Volumn 12, Issue 5, 2005, Pages 599-605

  Aaberge, Ingeborg S ^a   Oster, Philipp ^b   Helland, Oddveig S ^a   Kristoffersen, Anne Cathrine ^a   Ypma, Ellen ^c   Høiby, E Arne ^a   Feiring, Berit ^a   Nøkleby, Hanne ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b CHIRON VACCINES   (Italy)

^c Chiron BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE;

ADULT; ARTICLE; BACTERIAL STRAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; EVALUATION; EYE PAIN; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE REACTION; MALAISE; MEMBRANE VESICLE; MENINGOCOCCOSIS; MUSCLE STIFFNESS; NAUSEA; NEISSERIA MENINGITIDIS; NORMAL HUMAN; OUTER MEMBRANE; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEROTYPE; SERUM BACTERICIDAL ACTIVITY; STIFF NECK;

ADULT; ANTIBODIES, VIRAL; ANTIBODY FORMATION; BACTERIAL OUTER MEMBRANE PROTEINS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; NEISSERIA MENINGITIDIS, SEROGROUP C; VACCINES, CONJUGATE;

EID: 23944498113     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.12.5.599-605.2005     Document Type: Article

References (23)

1. Bethell, D., and A. J. Pollard. 2002. Meningococcal vaccines. Expert Rev. Vaccines 1:75-84.
2. Bjune, G., E. A. Høiby, J. K. Grønnesby, O. Arnesen, J. H. Fredriksen, A. Halstensen, et al. 1991. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338:1093-1096.
3. Cano, R., A. Larrauri, S. Mateo, B. Alcalá, C. Salcedo, and J. A. Vázquez. 2004. Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision. Euro Surveill. 9:5-6.
4. Connolly, M., N. Noah, and the European Meningitis Surveillance Group. 1999. Is group C meningococcal disease increasing in Europe? A report of surveillance of meningococcal infection in Europe 1993-6. Epidemiol. Infect. 122:41-49.
5. De Wals, P., L. Hertoghe, I. Borlee-Grimee, S. De Maeyer-Cleempoel, G. Reginster-Haneuse, A. Dachy, et al. 1981. Meningococcal disease in Belgium. Secondary attack rate among household, day-care nursery and pre-elementary school contacts. J. Infect. 3(Suppl. 1):53-61.
6. Dyet, K., A. Devoy, R. McDowell, and D. Martin. 2005. New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery. Vaccine 23:2228-2230.
7. Feiring, B., L. M. Næss, J. Fuglesang, E. Rosenqvist, M. A. R. Bergsaker, A. Haugan, et al. 2004. Antibody responses against homologous and heterologous meningococcal serogroup B strains after a fourth dose of a meningococcal serogroup B OMV vaccine (MenBvac). Abstracts of the 14th International Pathogenic Neisseria Conference, Milwaukee, Wis., p. 154. (www.neisseria.org.)
8. Fredriksen, J. H., E. Rosenqvist, E. Wedege, K. Bryn, G. Bjune, L. O. Frøholm, et al. 1991. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH (Natl. Inst. Public Health) Ann. 14:67-79.
9. Granoff, D. M., S. E. Maslanka, G. M. Carlone, B. D. Plikaytis, G. F. Santos, A. Mokatrin, et al. 1998. A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses. Clin. Diagn. Lab. Immunol. 5:479-485.
10. Høiby, E. A., E. Rosenqvist, L. O. Frøholm, G. Bjune, B. Feiring, H. Nøkleby, et al. 1991. Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey. NIPH (Natl. Inst. Public Health) Ann. 14:147-155.
11. Martin, D. R., S. J. Walker, M. G. Baker, and D. R. Lennon. 1998. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J. Infect. Dis. 177:497-500.
12. Maslanka, S. E., L. L. Gheesling, D. E. Libutti, K. B. J. Donaldson, H. S. Harakeh, J. K. Dykes, et al. 1997. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin. Diagn. Lab. Immunol. 4:156-167.
13. Næss, L. M., T. Tangen, A. C. Kristoffersen, I. S. Aaberge, E. A. Høiby, and E. Rosenqvist. 2002. Immunogenicity of a combination of two different outer membrane protein based meningococcal group B vaccines. In D. A. Caugant and E. Wedege (ed.), Abstracts of the 13th International Pathogenic Neisseria Conference, Oslo, Nordberg Aksidenstrykkeri AS, Oslo, Norway, p. 284.
14. Nøkleby, H., and B. Feiring. 1991. The Norwegian meningococcal group B outer membrane vesicle vaccine: side effects in phase II trials. NIPH (Natl. Inst. Public Health) Ann. 14:95-102.
15. Rosenqvist, E., E. A. Høiby, E. Wedege, K. Bryn, J. Kolberg, A. Klem, et al. 1995. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect. Immun. 63:4642-4652.
16. Rosenqvist, E., E. A. Høiby, G. Bjune, A. Aase, A. Halstensen, A. K. Lehmann, et al. 1998. Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine. Dev. Biol. Stand. 92:323-333.
17. Rosenqvist, E., S. Harthug, L. O. Frøholm, E. A. Høiby, K. Bøvre, and W. D. Zollinger. 1988. Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection. J. Clin. Microbiol. 26: 1543-1548.
18. Santos, G. F., R. R. Deck, J. Donnelly, W. Blackwelder, and D. M. Granoff. 2001. Importance of complement source in measuring meningococcal bactericidal titers. Clin. Diagn. Lab. Immunol. 8:616-623.
19. Sexton, K., D. Lennon, P. Oster, I. Aaberge, D. Martin, S. Reid, et al. 2004. Proceedings of the Meningococcal Vaccine Strategy World Health Organization Satellite Meeting, 10 March 2004, Auckland, New Zealand. N. Z. Med. J., vol. 117, no. 1200, ISSN 1175 8716.
20. Sexton, K., D. Lennon, P. Oster, S. Crengle, D. Martin, K. Mulholland, et al. 2004. The New Zealand meningococcal vaccine strategy: a tailor-made vaccine to combat a devastating epidemic. N. Z. Med. J., vol. 117, no. 1200, ISSN 1175 8716.
21. Tappero, J. W., R. Lagos, A. M. Ballesteros, B. Plikaytis, D. Williams, J. Dykes, et al. 1999. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines. A randomized controlled trial in Chile. JAMA 281:1520-1527.
22. Wenger, J. D., and B. A. Perkins. 1998. Patterns in the emergence of epidemic meningococcal disease, p. 125-136. In W. M. Scheid, D. Armstrong, and J. M. Hughes (ed.), Emerging infectious diseases, vol. 1. ASM Press, Washington, D.C.
23. Zhang, Q., E. Pettitt, R. Burkinshaw, G. Race, L. Shaw, and A. Finn. 2002. Mucosal immune responses to meningococcal conjugate polysaccharide vaccines in infants. Pediatr. Infect. Dis. J. 21:209-213.